Cyprium Therapeutics Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cyprium Therapeutics Inc.
Zydus Lifesciences is building a rare disease-focused pipeline as a differentiating strategy, managing director Sharvil Patel tells Scrip in an interview. Innovation and patient centricity at heart, digital initiatives are being implemented to transform the company into a ‘future ready’ healthcare organization
Zydus Cadila sees 40-50% growth continuing in its biosimilars business, with plans for launches in Latin America. Its Kadcyla biosimilar is faring well and after helping the company gain the top spot in India, could also move to clinical trials in the US.
Keeping Track: Spectrum Submits Poziotinib; US FDA Approves Daré’s Xaciato, Expands Heron Zynrelef Label
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Deal Snapshot: Sentynl will pay $20m in upfront and regulatory milestone payments through FDA approval, while Cyprium will retain 100% ownership of the priority review voucher.
- Specialty Pharmaceuticals